ClinicalTrials.gg
RecruitingNCT07472543VR-LELOUpdated Mar 16, 2026

Impact of Virtual Reality (VR) Based Exercises on Lower Limb Lymphedema Outcomes (LELO)

An interventional study of Complex Decongestive Therapy (CDT) plus virtual reality (VR)-assisted gait training group and Complex Decongestive Therapy alone group in Lymphedema, Gait Dysfunction and Physical Rehabilitation, sponsored by Gaziler Physical Medicine and Rehabilitation Education and Research Hospital. Recruiting at 2 sites in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Gaziler Physical Medicine and Rehabilitation Education and Research Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Lymphedema with a site in Turkey — 12 open to participants now, 16 under way, none of them phase 3. Lymphedema · Turkey.

Planned enrollment
23rd of 45
40 · median 40
Started
2025
with 9 others
No phase
44 of 65
11 open now
Primary completion
2026-09
later than 7 of 15 live
Registered
49th of 65
by date
Lead sponsor
2 of 65
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital

Among the 65 studies in Lymphedema with a site in Turkey, this one is the 23rd largest by planned enrollment of the 45 interventional ones that give a count, is one of 10 that started in 2025, is one of 44 with no phase, reaches primary completion later than 7 of the 15 other live ones, and was the 49th registered.

Lymphedema

529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.

Browse Lymphedema studies →

Open to participants now

12 of the 65 studies in Lymphedema with a site in Turkey are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 84 Lymphedema studies recruiting now, 46 (55%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Lymphedema with a site in Turkey, or all of them as a file.
02

Study summary

This randomized controlled study aims to investigate the effects of virtual reality (VR)-assisted gait training, in addition to Complex Decongestive Therapy (CDT), on gait parameters, physical function, quality of life, and edema levels in patients with lower extremity lymphedema. Lymphedema is a progressive condition characterized by the accumulation of protein-rich fluid due to lymphatic drainage insufficiency, leading to chronic inflammation and fibrosis. It impairs gait patterns and reduces functional mobility. VR technologies, such as the RehaWalk system, provide interactive, personalized rehabilitation environments that enhance motor learning, motivation, and adherence to treatment. The study evaluates spatiotemporal gait parameters, three-zone foot analysis (heel, midfoot, forefoot), limb circumferences, ultrasound measurements (dermis, epidermis, subcutaneous fat thickness), and patient-reported outcomes. VR-based training offers a novel, engaging approach to improve physical rehabilitation outcomes in patients with lower limb lymphedema. No significant risks are expected in this study.

03

Conditions studied

  • Lymphedema
  • Gait Dysfunction
  • Physical Rehabilitation
  • Chronic Edema

Browse trials for

Keywords

  • lymphedema
  • virtual reality exercises
  • ultrasonography
  • Gait Analysis
  • Spatiotemporal Parameters
  • Complex Decongestive Therapy (CDT)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65 years
  • Diagnosis of unilateral lower extremity lymphedema following gynecological and/or oncological surgery
  • Stage 2 or 3 lymphedema

Exclusion criteria

Exclusion Criteria:

  • Decompensated heart, lung, or kidney failure
  • Uncontrolled hypertension
  • Presence of systemic infection
  • Local infections in the lower extremity such as erysipelas or cellulitis
  • Venous insufficiency (e.g., deep vein thrombosis)
  • Any neuromuscular or orthopedic disease affecting lower extremity walking
  • Presence of balance disorders
  • Bilateral lymphedema
  • Presence of lipolymphedema
  • Fracture in the lower extremity
  • Active
  • Speech or language problems
  • Pregnancy
  • Inability to continue treatment (5 days a week for a total of 4 weeks)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Other
    Complex Decongestive Therapy alone group

    The control group will receive only the standard Complex Decongestive Therapy (CDT). This treatment will be administered daily and consists of manual lymphatic drainage for 20 minutes, multi-layer compression bandaging for 10 minutes, skin and nail care for 5 minutes, patient education for 5 minutes, and therapeutic exercises including joint range of motion, stretching, and breathing exercises for 20 minutes. No virtual reality or additional gait training interventions will be applied to this group. Assessments will be conducted before and after the 4-week treatment period to evaluate the effects of CDT alone on functional capacity, quality of life, edema levels, and walking parameters.

    Other: Complex Decongestive Therapy alone group

  • Active comparator
    Complex Decongestive Therapy (CDT) plus virtual reality (VR)-assisted gait training group

    The intervention group will receive standard Complex Decongestive Therapy (CDT) combined with virtual reality (VR)-supported walking exercises using the Rehawalk device. The Rehawalk system, which provides visual and auditory step guidance within a virtual environment, will be used to conduct the walking exercises at Gaziler Physical Therapy and Rehabilitation Training and Research Hospital. Participants will perform the VR-supported walking exercises for 20 minutes, five days a week, under the supervision of a physiotherapist. During these exercises, the affected lower limb will be multi-layer bandaged according to the standard CDT protocol. This combined treatment approach aims to improve gait parameters, functional capacity, edema control, and overall quality of life. Assessments will be carried out before and after the 4-week treatment period to evaluate the added benefits of VR-supported walking exercises alongside standard CDT.

    Procedure: Complex Decongestive Therapy (CDT) plus virtual reality (VR)-assisted gait training group

Interventions

  • ProcedureComplex Decongestive Therapy (CDT) plus virtual reality (VR)-assisted gait training group

    The intervention group will receive standard Complex Decongestive Therapy (CDT) combined with virtual reality (VR)-supported walking exercises using the Rehawalk device. The Rehawalk system, which provides visual and auditory step guidance within a virtual environment, will be used to conduct the walking exercises at Gaziler Physical Therapy and Rehabilitation Training and Research Hospital. Participants will perform the VR-supported walking exercises for 20 minutes, five days a week, under the supervision of a physiotherapist. During these exercises, the affected lower limb will be multi-layer bandaged according to the standard CDT protocol. This combined treatment approach aims to improve gait parameters, functional capacity, edema control, and overall quality of life. Assessments will be carried out before and after the 4-week treatment period to evaluate the added benefits of VR-supported walking exercises alongside standard CDT.

  • OtherComplex Decongestive Therapy alone group

    The control group will receive only the standard Complex Decongestive Therapy (CDT). This treatment will be administered daily and consists of manual lymphatic drainage for 20 minutes, multi-layer compression bandaging for 10 minutes, skin and nail care for 5 minutes, patient education for 5 minutes, and therapeutic exercises including joint range of motion, stretching, and breathing exercises for 20 minutes. No virtual reality or additional gait training interventions will be applied to this group. Assessments will be conducted before and after the 4-week treatment period to evaluate the effects of CDT alone on functional capacity, quality of life, edema levels, and walking parameters.

06

What researchers measure

Primary outcomes

  1. Gait parameters

    Spatiotemporal gait parameters (walking speed, cadence, step length, stride length, stance time, swing time) and plantar pressure distribution (peak pressure and contact time in heel, midfoot, and forefoot regions) will be assessed using the Rehawalk® instrumented treadmill system (zebris Medical GmbH, Germany). All parameters will be reported as individual continuous variables. Participants will walk barefoot at self-selected comfortable speed; data will be recorded for 30-60 seconds during steady-state walking after 1-2 minutes adaptation.

    Time frame: Assessments will be conducted immediately before the treatment starts and at the end of the treatment (week 4).

  2. Lower extremity circumferential volume measurements

    Circumferential measurements will be performed on the affected extremity with the patient in a semi-seated position, the ankle in neutral and the knee in extension. Measurements will begin at the ankle (medial malleolus) and continue at 4 cm intervals up to the inguinal region. After treatment, all patients' lymphedematous extremities (unilateral) will be measured a second time by the same evaluator using the same method, and the measurements will be recorded. The measurement data will be used to calculate the volume of the limb segments using the frustum formula for truncated cones, processed via Microsoft Excel. Pre- and post-treatment circumferential measurement data will be entered into the program to calculate extremity volumes and volume differences between extremities (in milliliters and percentage).

    Time frame: Assessments will be conducted immediately before the treatment starts and at the end of the treatment (week 4).

Secondary outcomes

  1. Dermal-epidermal thickness and subcutaneous tissue thickness measured by ultrasonography (USG)

    Ultrasonographic evaluation will include measurement of the dermo-epidermal complex thickness, subcutaneous tissue thickness, and subcutaneous fluid accumulation. Additionally, sonographic pattern analysis will be performed to assess homogeneity, differences in echogenicity, fibrotic bands, and irregularities. Other findings such as lymphatic lakes and fascial delamination will also be evaluated.

    Time frame: Assessments will be conducted immediately before the treatment starts and at the end of the treatment (week 4).

  2. Quality of life assessment -Lymphedema Quality of Life Questionnaire-Leg (LYMQOL-Leg)

    Lymphedema Quality of Life Questionnaire-Leg (LYMQOL-Leg): This is a disease-specific quality of life scale for patients with lymphedema, consisting of 22 questions organized into 4 sections.Each item is scored on a 4-point Likert scale. Domain scores range from 0 to 7, with higher scores indicating worse quality of life. An overall quality of life item is scored from 0 to 10, with higher scores indicating better overall quality of life.

    Time frame: Assessments will be conducted immediately before the treatment starts and at the end of the treatment (week 4).

  3. Functional capacity - Timed Up and Go Test (TUG)

    Functional capacity assessment using the Timed Up and Go Test (TUG). Timed Up and Go Test (TUG): This test measures the speed at which patients perform several functional maneuvers including standing up from a chair, walking, turning, and sitting down.

    Time frame: Assessments will be conducted immediately before the treatment starts and at the end of the treatment (week 4).

  4. Functional status - Lower Extremity Functional Scale (LEFS)

    Functional status will be evaluated using the Lower Extremity Functional Scale (LEFS). This questionnaire consists of 20 items assessing the patient's ability to perform daily activities involving the lower extremities. Each item is scored from 0 to 4, resulting in a total score ranging from 0 to 80, with higher scores indicating better functional condition.

    Time frame: Measurements will be taken at baseline (before treatment) and after 4 weeks of treatment.

07

Study locations

2 of 2 sites recruiting
  • Ankara Gaziler physical therapy and rehabilitationhospital
    Ankara, 06680, Turkey (Türkiye)
    Recruiting
  • Gaziler physical therapy and rehabilitation
    Ankara, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2026, 12 months after the start.

Of 175 non-industry interventional studies with no phase under Lymphedema, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 68. This study's planned 12 months is below that.

Counting every sponsor, half of 197 studies reached it within 25 months; a quarter within 11 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Mar 16, 2026
StartActual
Sep 1, 2025
Primary completionEst.
Sep 1, 2026
CompletionEst.
Oct 1, 2026
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07472543
Lead sponsor
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital
Responsible party
Sefa Gümrük Aslan (Assistant professor, Gaziler Physical Medicine and Rehabilitation Education and Research Hospital) — Principal investigator
First posted
Mar 16, 2026
Start date
Sep 1, 2025
Primary completion
Sep 1, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Mar 16, 2026

Study contacts

SEFA GÜMRÜK ASLAN
Contact
sefagumrukk@gmail.com
+903122911503
sefa gümrük aslan, M.D.
Contact
sefagumrukk@gmail.com
+903122911503

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion